Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) announced today that it registered a trade name, “The Stem Cell Group,” for use in marketing and branding its subsidiary company, Celulas Genetica.
Celulas Genetica is a biotechnology firm that EHSI acquired last December. Headquartered in Panama City, Panama, Celulas Genetica is a Central American leader in stem-cell technology acquisition and development. The company was acquired by EHSI after purchasing a license to develop and market the Rutherford Procedure, a groundbreaking organ regeneration treatment designed to use proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells.
“Celulas Genetica will play a crucial role in the development of the Rutherford Procedure,” said EHSI President and CEO Cindy Morrissey. “Under the trade name ‘The Stem Cell Group,’ we believe this important subsidiary of EHSI will be more attractive to potential partners and investors around the world.”
In January, Celulas Genetica opened a new business office located in the Chaoyang District of Beijing, a region of the Chinese capital that is home to many foreign embassies and business headquarters. It was a crucial first step for the company in its mission to test and perfect the Rutherford Procedure using EHSI’s NASA bioreactor.
The Intrifuge Rotary Cell Culture SystemTM, a rotating-wall bioreactor originally designed by NASA to facilitate the growth of human stem cells in simulated weightlessness, is key to EHSI’s plan to commercialize and develop The Rutherford Procedure. Stem cell cultures grown inside the bioreactor look and function much closer to cells grown within the body than cell cultures grown in Petri dishes.
Earlier this year, EHSI acquired a license to use the bioreactor to expand adult stem cells in China and elsewhere outside of the U.S. Stem cell expansion is a crucial component of the Rutherford Procedure, as a multitude of high-quality adult stem cells is extremely beneficial for regenerating patients’ damaged livers into healthy, functioning organs once more.
For more information on Celulas Genetica and the Rutherford procedure, please visit http://www.TheStemCellGroup.com.
The Stem Cell Group is planned to serve as a major outpost in EHSI’s global footprint. In addition to the Stem Cell Group’s headquarters in Panama and business office in China, EHSI also maintains offices in Germany and Poland.
EHSI invests in technology developed to compete in the stem-cell research industry alongside Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), Allergan, Inc. (NYSE: AGN), Smith & Nephew (NYSE: SNN) and Forest Laboratories, Inc. (NYSE: FRX).
About Emerging Healthcare Solutions, Inc.
Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.
For more information, please visit http://www.EmergingHealthcareSolutionsInc.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.